{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Adaprolol is a beta-adrenergic antagonist that is being developed as a topical agent to treat glaucoma. Adaprolol demonstrated a safer cardiovascular profile, especially in the population over 70 years old. It was in Phase II clinical trials for the treatment of glaucoma. This research has been discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Daltroban (also known as BM 13505, SKF 96148), a specific thromboxane A2 receptor antagonist, was studied as an antithrombotic agent. The drug was licensed to Smith Kline Beecham, underwent phase III clinical trials in the UK and Germany as an antithrombotic agent but did not enter clinical trials in the USA. Besides, вaltroban was investigated in patients with an ischemic heart disorder. However, the development of daltroban has been discontinued.
Status:
Investigational
Source:
NCT00664378: Phase 2 Interventional Terminated Relapsed and Refractory Multiple Myeloma
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
CYT997 (Lexibulin) is a wholly synthetic compound that possesses highly potent cytotoxic activity in vitro through inhibition of microtubule polymerization. CYT997 (Lexibulin) is a potent microtubule polymerization inhibitor with IC50 of 10-100 nM in cancer cell lines. CYT997 (Lexibulin) blocks the cell cycle at the G(2)-M boundary, and Western blot analysis indicates an increase in phosphorylated Bcl-2, along with increased expression of cyclin B1. Caspase-3 activation is also observed in cells treated with CYT997 (Lexibulin) along with the generation of poly(ADP-ribose) polymerase. The compound possesses favorable pharmacokinetic properties, is orally bioavailable, and is efficacious per os in a range of in vivo cancer models, including some refractory to paclitaxel treatment. CYT997 (Lexibulin) exhibits vascular disrupting activity as measured in vitro by effects on the permeability of human umbilical vein endothelial cell monolayers, and in vivo by effects on tumor blood flow. CYT997 (Lexibulin) possesses a useful combination of pharmacologic and pharmacokinetic properties having considerable potential as a novel anticancer agent. Lexibulin was being developed by YM BioSciences as a vascular-disrupting agent (VDA) for the potential treatment of cancer, it was in phase II development on YM BioSciences ' pipeline. It appears that the development of lexibulin has been discontinued.
Status:
Investigational
Source:
INN:closiramine [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Clorisamine is an antihistamine drug developed by Schering in the 1970s. The drug was evaluated in phase 1 clinical trial on healthy volunteers. The results show that in a therapeutic dose of 2 mg the drug did not have any effects which might lead to an impairment of driving ability.
Status:
Investigational
Source:
INN:ethylmethylthiambutene [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Ethylmethylthiambutene is a potent analgesic compatible with morphine. It possesses addiction liability similar to that of morphine.
Status:
Investigational
Source:
NCT00358488: Phase 2 Interventional Completed Pulmonary Disease, Chronic Obstructive
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Milveterol (also known as GSK159797) was developed as a longer-acting beta2 adrenoceptor agonist for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Milveterol completed phase II clinical trials for asthmatic subjects. However further development of the drug was discontinued.
Status:
Investigational
Source:
INN:peliglitazar [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Peliglitazar (also known as BMS 426707-01), a dual α/γ peroxisome proliferator-activated receptor agonist, has been studied in phase I/II clinical trial in patients with type 2 diabetes mellitus. However, this study was discontinued.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
JAN:INAPERISONE HYDROCHLORIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Inaperisone is a pyrrolidinopropiophenone derivative patented by Japanese pharmaceutical company Hokuriku Pharmaceutical Co. as muscle-relaxant and antispasmodic agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Dopamantine is the adamantine derivative. It combined elements of both amantadine and dopamine in its structure, shares some pharmacological effects of amantadine. Dopamantine is the anti-Parkinson drug, which has passed clinical trials. Dopamantine showed a high activity against Plasmodium berghei parasites that cause malaria.
